SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing extreme volatility driven by a conflicting narrative between a market-moving announcement from Donald Trump regarding a potential ceasefire with Iran and immediate, emphatic denials from Iranian state media. The community is sharply divided, with bulls cheering the prospect of de-escalation and potential liquidity injections, while bears and skeptics are accusing the administration of cynical market manipulation to stave off a broader sell-off.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility driven by a combination of broader macroeconomic headwinds, including rising oil prices and interest rate uncertainty, and a persistent, high-profile short report from Muddy Waters that has sparked intense debate over the company's accounting practices and growth sustainability. While some investors are bracing for further downside and expressing skepticism, a vocal segment of the community remains focused on CEO Anthony Noto's recent insider buying as a signal of long-term conviction and potential undervaluation.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is experiencing intense volatility as investors react to conflicting headlines regarding potential ceasefire talks with Iran, with community sentiment split between skepticism over potential market manipulation and hopes for a de-escalation of regional tensions. Traders are actively debating the authenticity of administration statements versus official denials from Tehran, leading to sharp price swings as the market gauges the broader impact of geopolitical uncertainty on tech and energy stocks.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing extreme volatility as market participants react to conflicting signals regarding the ongoing conflict with Iran, including unsubstantiated reports of imminent ceasefire talks and threats of further infrastructure strikes. Community discourse remains deeply divided between those betting on a prolonged supply crunch and those anticipating rapid de-escalation, all while traders adjust their positions to navigate the unpredictable impact of geopolitical headlines on crude prices.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is at the center of significant investor enthusiasm following the removal of its CEO and key management team, signaling a major leadership overhaul that stakeholders hope will unlock shareholder value. The community is actively debating the potential for an imminent buyout or strategic sale, closely monitoring the influence of major shareholder Kevin Tang as they look for progress on the company's pipeline and patent negotiations.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna is trending due to a significant volume surge and investor interest driven by supply chain disruptions in the Middle East following infrastructure damage to major LNG facilities. The community is actively debating the stock's potential for further upward movement amidst geopolitical tensions, while keeping a close watch on technical support levels and the risk of volatility common in low-float energy plays.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as investors react to high-stakes political maneuvering in the Middle East, with community discussion sharply divided over the potential for a market-moving deal versus concerns about escalating geopolitical risks. Traders remain hyper-focused on the stock's sensitivity to headline-driven volatility, fueling intense debate regarding its role as both a platform for discourse and a barometer for the current administration's market influence.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is trending as traders closely monitor geopolitical tensions in the Middle East and their impact on energy prices and broader market sentiment. The community is actively debating the reliability of ceasefire headlines, with many investors adjusting their portfolios to hedge against volatility while navigating conflicting signals regarding Fed rate policy.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors react to a bipartisan Senate bill aimed at banning sports betting contracts on prediction markets like Polymarket and Kalshi. While community sentiment remains split on the stock's long-term volatility and management's handling of aggressive growth, many traders are closely watching the potential for the company to leverage its established sportsbook infrastructure against newer prediction market competitors.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil (SCO) is attracting heavy volume as traders pivot to hedge against or bet against the recent volatility in crude oil prices driven by geopolitical tensions in the Strait of Hormuz. While some investors are scaling into the position expecting a eventual normalization in oil supply and a price correction, the community is actively debating the impact of the ETF's daily decay and the potential for rapid price swings as news regarding energy infrastructure and global strategic reserve releases continues to emerge.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuron (IMRN) CEO Steven Lydeamore stated in a letter to shareholders on Thursday that the company does not anticipate any material impact from the recently announced U.S. tariffs on pharmaceutical products.Nasdaq-listed shares of Immuron rallied 8% on Thursday morning following the news. The CEO <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160195/37134/en/Immuron-Letter-to-Shareholders-Projects-Update.html">stated</a> that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs.The Australia-based company also said that it is on track to exceed FY24 first-quarter (Q1) sales. The company is slated to report its Q1 FY25 sales in mid-October.Immuron has three therapeutic products under development, including IMM-124E, also known as Travelan, for traveler’s diarrhea. The company stated that it continues to expect trial results for this candidate in October 2025.“It is hoped that this trial will enable Travelan to be recommended in traveler’s diarrhea guidelines, thereby increasing its market potential,” the company said.As for IMM-529, which is under development for Clostridioides difficile infection, Immuron stated that it is progressing with an application to the U.S. Food and Drug Administration to initiate clinical development by mid-October. According to Immuron, the IMM-529 market in the U.S. is expected to reach peak revenues of approximately $400 million.The company has also advanced the launch of ProIBS, a medical product for treating symptoms related to Irritable Bowel Syndrome, to the fourth quarter from its previous estimate of Q1 2026. Immuron now anticipates a limited launch in Q4, with a full launch in Q1 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMRN">IMRN stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:574/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_12_28_03_PM_png_c36282e1fb.webp" alt="IMRN's Sentiment Meter and Message Volume as of 12:28 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="574" height="58"><figcaption>IMRN's Sentiment Meter and Message Volume as of 12:28 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the company’s updates.<stembedurl>https://stocktwits.com/Timtheshark/message/630768842</stembedurl>IMRN stock is up 22% this year but down approximately 24% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reports-7-percent-rise-in-q3-deliveries/chCrXlDR3Ow">Tesla’s Q3 Deliveries Hit Quarterly Record, Rise 7% To Exceed Analyst Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 

Equity

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 


Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

Current Price	$0.703
Prev Close	$0.709
Open	$0.7031
Dividend Yield	0.00%
50-Day Moving Average	$0.8398
Beta	0.80
Avg. Volume	21,041.35
PE Ratio	-1.46

52-Week High	$2.39
52-Week Low	$0.6765
Market Capitalization	$5.74M
EPS (Annual)	-$0.5852
Price to Book	0.66
Revenue Per Employee	N/A

IMRN
IMMURON Ltd/S ADR

Feed

News

Sentiment

Fundamentals

Info

Latest IMRN News

IMRNIMMURON Ltd/S ADR